Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline

14 hours ago 2

Jonathan Ponciano, The Motley Fool

Fri, March 13, 2026 astatine 9:34 AM CDT 4 min read

On February 17, 2026, Deerfield Management Company disclosed a bargain of Praxis Precision Medicines (NASDAQ:PRAX), adding 62,500 shares successful a commercialized estimated astatine $11.64 cardinal based connected quarterly mean pricing.

According to a filing with the U.S. Securities and Exchange Commission connected February 17, 2026, Deerfield Management Company purchased an further 62,500 shares of Praxis Precision Medicines. The estimated transaction worth was $11.64 million, calculated utilizing the mean closing terms for the 4th fourth of 2025. The fund’s PRAX position’s worth accrued by $221.69 cardinal implicit the quarter, a alteration that includes some trading enactment and banal terms movement.

Following the buy, the PRAX involvement represented 3.4% of Deerfield Management Company’s 13F reportable AUM arsenic of December 31, 2025.
Top 5 holdings aft the filing:
- NASDAQ: NUVL: $1.74 cardinal (25.4% of AUM)
- NASDAQ: COGT: $321.24 cardinal (4.7% of AUM)
- NASDAQ: PRAX: $266.25 cardinal (3.9% of AUM)
- NYSE: CNC: $265.34 cardinal (3.9% of AUM)
- NASDAQ: VTRS: $251.57 cardinal (3.7% of AUM)
As of Friday, shares of PRAX were priced astatine $303.37, up a staggering 685% implicit the past twelvemonth and vastly outperforming the S&P 500’s astir 19% summation successful the aforesaid period.

Metric

Value

Price (as of Friday)	$303.37
Market capitalization	$8.7 billion
Net income (TTM)	($303.3 million)

Praxis Precision Medicines develops clinical-stage therapies for cardinal tense strategy disorders, with pb candidates targeting large depressive disorder, indispensable tremor, and uncommon epilepsies.
The institution generates gross chiefly done licensing agreements, probe collaborations, and milestone payments tied to its biopharmaceutical pipeline.
Praxis targets healthcare providers and patients affected by neurological and psychiatric conditions, focusing connected unmet aesculapian needs successful neurology and psychiatry.

Praxis Precision Medicines is simply a Boston-based biotechnology institution specializing successful the improvement of caller therapies for cardinal tense strategy disorders. With a portfolio of differentiated merchandise candidates successful assorted objective stages, the institution leverages strategical collaborations and licensing agreements to beforehand its pipeline and money operations. Praxis's absorption connected innovative treatments for neurological and psychiatric diseases positions it arsenic a cardinal subordinate addressing important unmet needs successful the healthcare sector.

Two of Praxis’ programs person crossed an important milestone that’s helped propulsion shares up by a staggering magnitude this past year. Last month, the institution said it submitted caller cause applications to the FDA for ulixacaltamide successful indispensable tremor and relutrigine successful uncommon developmental epilepsies portion besides preparing for further Phase 3 readouts aboriginal this year. Together, absorption believes the 4 starring programs successful improvement could correspond much than $20 cardinal successful imaginable gross if successfully commercialized.

Financially, Praxis is well-positioned to prosecute that opportunity. The institution ended 2025 with astir $926 cardinal successful currency and investments, and a follow-on offering successful aboriginal 2026 added different $621 million, extending its expected runway into 2028.

For semipermanent investors, the question present shifts from find to execution. If adjacent a information of that neuroscience pipeline reaches the market, Praxis could germinate from a clinical-stage biotech into a multi-product neurology franchise. Of course, shares volition beryllium taxable to lofty expectations and imaginable volatility on the way.

Read Entire Article